临床药物遗传学实施联盟关于NAT2基因型和拉治疗的指导方针
Michael T Eadon1, David W Hein2, Michael A Andersen3
1Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
低N-乙转移酶2 (NAT2) 代谢者可能会经历更高的拉水平,可能会增加有效性和副作用,如药物诱导的狼. 本指南提供了基于NAT2基因型的处方建议.
科学领域:
- 药物基因组学 药物基因组学
- 药物新陈代谢 药物新陈代谢
- 心血管治疗学心血管治疗学
背景情况:
- 海德拉是高血压和心力衰竭的血管扩张剂.
- N-乙转移酶2 (NAT2) 将氨酸代谢成不活性形式.
- NAT2基因型影响氨酸代谢和患者的反应.
研究的目的:
- 审查有关NAT2和拉相互作用的文献.
- 提供基于证据的推,对拉的处方.
- 根据NAT2基因型预测的乙化剂表型指导临床实践.
主要方法:
- 对NAT2/拉的证据进行文献综述.
- 对NAT的基因型-表型相关性的分析2.2.
- 制定临床实践指南.
主要成果:
- 预计NAT2低代谢者具有更高的氨酸度.
- 度的增加可能会导致疗效的提高和不良事件,包括药物诱导的全身性红斑狼.
- NAT2基因型影响拉的药理动力学和药理动力学.
结论:
- NAT2基因型影响了拉治疗的结果.
- 根据NAT2乙化剂表型处方拉可以优化治疗.
- 在www.cpicpgx.org上更新指南以获得当前的建议.
更多相关视频
10:28Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
Published on: December 5, 2017
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Dosage Regimen: Individualization
Antihypertensive Drugs: Vasodilators
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Hypertension IV: Drug Therapy and Lifestyle Modifications
